Learn

Breast Cancer Practice Review Issue 2. Content has been reviewed by Dr Hilary Martin.

This Review covers news and issues relevant to clinical practice in Breast Cancer. It will bring you the latest updates, both locally and from around the globe, about topics such as new and updated treatment guidelines, changes to medicines reimbursement and licensing, educational, professional body news and more. Finally, on the back cover, you will find a summary of upcoming local and international educational opportunities, including workshops, webinars, and conferences.

Details

This is intended to keep you up to date with other factors that affect your daily practice outside of clinical research. Content has been reviewed by Dr Hilary Martin.

In this issue we feature:

• Pan-Asian adapted guidelines for early breast cancer diagnosis and treatment
• ESMO metastatic breast cancer living guideline
• PBS listings         
• Olaparib subsidised for BRCA1/2 mutated metastatic breast cancer         
• Restriction on funded BRCA gene mutation testing removed 
• PBAC recommendations
• Co-dependent PBAC/MSAC submissions
• MBS items under consideration
• US approves inavolisib for endocrine-resistant PIK3CA-mutated breast cancer
• Upcoming PBAC agenda
• PBS co-payment freeze
• New restrictions on paracetamol products
• Timeframe for Centrelink medical certificates increased
• Prediagnostic BRCA testing linked to better outcomes
• RAD51 test may enable personalised neoadjuvant treatment for early disease
• COVID-19 resources
• Conferences & Workshops

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.